Drug intelligence / Profile preview

ianalumab + lenalidomide

Development stage: Preclinical
Lead developer: Novartis
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

ianalumab + lenalidomide is an experimental combination therapy consisting of ianalumab, a monoclonal antibody targeting B-cell activating factor receptor (BAFF-R), and lenalidomide, an immunomodulatory small molecule. Lenalidomide works by binding cereblon and modulating the immune system, direct tumor cell cytotoxicity, and inhibiting angiogenesis, widely used in multiple myeloma and other hematologic malignancies. The combination is under evaluation for enhanced antitumor immune response and clinical benefit in blood cancers, including multiple myeloma.

Targets

IKZF3 (Zinc finger protein Aiolos)CRBN (Cereblon)TNFRSF13C (B-cell Activating Factor Receptor)IKZF1 (Ikaros family zinc finger protein 1)

Beyond the preview

Go deeper on ianalumab + lenalidomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ianalumab + lenalidomide.

Explore the full profile